2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - La Nouvelle A-B
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Combination Therapy, Adverse Events, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Study Population, Human, Adult
PAPER

818 Transcriptional rewiring through regional haploinsufficiency defines del(1p32) multiple myeloma

Hanne Marie Liddle Norseth, MD, Jessica Encinas Mayoral, PhD2, Joshua Rivera, Ph.D.3, Anil Aktas-Samur, PhD4, Xingping Qin5, Kristopher Sarosiek6, Tallya Maciel7, Yuanyuan Jin, MD8, Anna Besschetnova, PhD9, Anais Schavgoulidze Jr, PharmD PhD10, Jill Corre Sr, PharmD11, Fredrik Schjesvold, MD,PhD12, Mehmet Kemal Samur, PhD13, Mariateresa Fulciniti, PhD14, Nikhil Munshi, MD15
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Oslo University Hospital, Oslo, Oslo, Norway, University of Oslo, Oslo, Norway
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
11 Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
12 Oslo University Hospital, Oslo, Oslo, Norway
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Background: Biallelic deletion of chromosome 1p32 [del(1p32)] has recently been incorporated into the updated International Myeloma Working Group (IMWG) risk classification as one of the highest-risk genomic abnormalities in newly diagnosed multiple myeloma (MM). Despite its strong association with early relapse and poor survival, the biological basis of its aggressive clinical behavior remains poorly understood. We sought to define the molecular basis of this high-risk subtype by integrating patient-derived multiomic datasets with a novel CRISPR-engineered cellular model that faithfully recapitulates del(1p32).

Methods: We combined genomic, transcriptomic and clinical analyses from three independent MM patient cohorts (CoMMpass, GAMER and IFM2009) with CRISPR-engineered isogenic del(1p32) MM models using the MACHETE technique. Functional studies evaluated proliferation, clonogenicity, apoptosis, immunogenicity and therapeutic response. Integrated gain and loss of function screens for both coding and non-coding genes were leveraged to identify genetic dependencies associated with del(1p32).

Results: Across all patient cohorts, biallelic del(1p32) was identified in 2–5% of newly diagnosed MM. Both biallelic and monoallelic del(1p32) were highly clonal at diagnosis, with cancer cell fractions exceeding 80% across patient cohorts. Integrated transcriptomic analyses of patient tumors revealed a shared transcriptional program characterized by activation of MYC, proliferation, cell-cycle, survival and immune-evasion pathways, together with coordinated dosage-dependent suppression of genes across the deleted interval. miRNA sequencing of IFM2009 samples further demonstrated significant enrichment of oncogenic miRNA clusters, including miR-17/92, miR-106a-363 and miR-506-514, in biallelic del(1p32), supporting extensive transcriptional rewiring and activation of proliferative programs.

Importantly, restoration or disruption of individual candidate genes within the deleted interval, including CDKN2C and FAF1, failed to fully recapitulate the phenotype, demonstrating that del(1p32) is not driven by loss of a single gene. Instead, our data support a model in which coordinated haploinsufficiency across the 1p32 interval rewires transcriptional and signaling networks to establish the aggressive disease state.

Using the MACHETE genome-engineering approach, we created an isogenic cell line by introducing a ~3.2 Mb deletion on chromosome 1p32 into a 1p-wild-type AMO1 MM cell line. We created both biallelic and single allele deleted cell lines. The engineered del(1p32) models faithfully reproduced patient biology, exhibiting accelerated proliferation and enhanced clonogenic capacity. These observations extended in vivo, where humanized MM mouse models bearing del(1p32) isogenic cells demonstrated accelerated tumor growth and significantly reduced animal survival compared with parental wild-type cells.

Notably, del(1p32) cells displayed features of immune evasion, including reduced surface HLA class II expression and impaired induction of immunogenic cell death following bortezomib treatment, as evidenced by diminished calreticulin surface exposure. Consistent with the clinically therapy-resistant phenotype, del(1p32) cells also displayed reduced apoptotic priming by BH3 profiling and decreased sensitivity to IMiDs and CELMoDs.

Together, these findings establish the first functional model of this newly recognized IMWG-defined high-risk MM subtype.

Finally, leveraging Cas13 functional genomics, we identified a selective dependency on a previously unrecognized long non-coding RNA whose elevated expression was associated with inferior clinical outcomes, thereby identifying a novel and potentially actionable therapeutic vulnerability in del(1p32) MM. Functional validation studies are underway to define its mechanistic role and evaluate its therapeutic potential.

Conclusions: Collectively, these findings demonstrate that the biological consequences of del(1p32) arise from coordinated regional haploinsufficiency rather than disruption of an individual driver gene, providing a mechanistic explanation for the aggressive clinical behavior associated with this lesion. Beyond providing mechanistic insight into a clinically important biomarker, this work identifies actionable coding and non-coding vulnerabilities that may enable the development of precision therapeutic strategies for patients with this ultra-high-risk genomic subtype.

Hanne Marie Liddle Norseth, MD: Oncopeptides - Honoraria; Bristol Myers Squibb Co - Honoraria; Johnson & Johnson - Honoraria; Circio Holding ASA - Honoraria; Menarini - Honoraria; Sanofi - Honoraria; Oncopeptides - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Bristol Myers Squibb Co - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Circio Holding ASA - Consultancy (Includes expert testimony)